{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:45Z","timestamp":1793747085611,"version":"4.6.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41395-018-0104-x","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T07:20:21Z","timestamp":1527837621000},"page":"883-889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials"],"prefix":"10.14309","volume":"113","author":[{"given":"Siddharth","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Proudfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210309","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0140-6736(14)60460-8","article-title":"Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013.","volume":"384","author":"Ng","year":"2014","journal-title":"Lancet"},{"key":"R2-19-20210309","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s10620-015-3629-5","article-title":"Obesity in inflammatory bowel disease: A marker of less severe disease.","volume":"60","author":"Flores","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R3-19-20210309","first-page":"2304","article-title":"Body mass index, genetic susceptibility, and risk of complications among individuals with Crohns disease.","volume":"21","author":"Pringle","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R4-19-20210309","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","article-title":"Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.","volume":"14","author":"Singh","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R5-19-20210309","doi-asserted-by":"crossref","first-page":"S976","DOI":"10.1016\/S0016-5085(17)33310-3","article-title":"Pre-morbid obesity is associated with increased risk of developing immune-mediated inflammatory diseases: a systematic review and meta-analysis.","volume":"152","author":"Singh","year":"2017","journal-title":"Gastroenterology"},{"key":"R6-19-20210309","doi-asserted-by":"crossref","first-page":"S973","DOI":"10.1016\/S0016-5085(17)33301-2","article-title":"Obesity is associated with worse disease activity in patients with inflammatory bowel diseases: An internet based cohort study.","volume":"152","author":"Jain","year":"2017","journal-title":"Gastroenterology"},{"key":"R7-19-20210309","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1097\/MIB.0000000000000560","article-title":"Impact of obesity on the management and clinical course of patients with inflammatory bowel disease.","volume":"21","author":"Seminerio","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R8-19-20210309","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.","volume":"55","author":"Hojgaard","year":"2016","journal-title":"Rheumatology"},{"key":"R9-19-20210309","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jbspin.2014.12.006","article-title":"Obesity reduces the drug survival of second line biological drugs following a first TNF-alpha inhibitor in rheumatoid arthritis patients.","volume":"82","author":"Iannone","year":"2015","journal-title":"Jt Bone Spine"},{"key":"R10-19-20210309","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.30136","article-title":"Body mass index and clinical response to infliximab in rheumatoid arthritis.","volume":"63","author":"Klaasen","year":"2011","journal-title":"Arthritis Rheuma"},{"issue":"5","key":"R11-19-20210309","doi-asserted-by":"crossref","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to antitumor necrosis factor- agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"R12-19-20210309","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/MEG.0b013e32835d1f15","article-title":"Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohns disease?.","volume":"25","author":"Bhalme","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R13-19-20210309","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1097\/MIB.0b013e31829cf401","article-title":"Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.","volume":"19","author":"Harper","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R14-19-20210309","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/19420862.2016.1216741","article-title":"The underlying inflammatory chronic disease influences infliximab pharmacokinetics.","volume":"8","author":"Passot","year":"2016","journal-title":"Mabs"},{"key":"R15-19-20210309","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcph.491","article-title":"Population pharmacokinetic analysis of certolizumab pegol in patients with Crohns disease.","volume":"55","author":"Wade","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"R16-19-20210309","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMp1607342","article-title":"The Yale Open Data Access (YODA) Project-A mechanism for data sharing.","volume":"375","author":"Krumholz","year":"2016","journal-title":"N Engl J Med"},{"key":"R17-19-20210309","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohns disease activity index. National Cooperative Crohns Disease Study.","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"R18-19-20210309","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/ajg.2010.143","article-title":"Appraisal of the pediatric Crohns disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties.","volume":"105","author":"Turner","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R19-19-20210309","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"R21-19-20210309","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar3841","article-title":"Body mass index influences the response to infliximab in ankylosing spondylitis.","volume":"14","author":"Ottaviani","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R22-19-20210309","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/bjs.1800790934","article-title":"Fat-wrapping in Crohns disease: pathological basis and relevance to surgical practice.","volume":"79","author":"Sheehan","year":"1992","journal-title":"Br J Surg"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0104-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0104-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/00000434-201806000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0104-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:45:59Z","timestamp":1786542359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201806000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1038\/s41395-018-0104-x","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}